Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.
- March 31, 2023
The T2Bacteria® Panel is the first and only FDA-cleared test to identify sepsis-causing bacteria directly from whole blood without the wait for blood culture.
Species identification in just hours: The commercially available T2Bacteria Panel provides species identification in 3 to 5 hours while the current standard of care takes 1 to 5 days or more.1 One T2Bacteria test result detects the equivalent of three sets of blood cultures for many species.2
Improved time to targeted therapy: By incorporating the Panel as part of the sepsis bundle, physicians can get more patients on the right therapy faster, thus improving empiric therapy protocols, potentially preventing the progression of sepsis, while increasing the chances of both patient survival and recovery.
Game-changing performance: In the T2Bacteria pivotal clinical trial1 conducted in 11 U.S. centers with 1,427 patients, investigators demonstrated:
Improved stewardship: Real-world clinical case studies have proven the clinical utility of both positive and negative results using the T2Bacteria Panel. Read our case study series to learn more.
Improved empiric therapy in the emergency department: Rapid diagnostics can significantly alter the early selection of appropriate therapy in patients with sepsis. Watch the 2018 video interview with two-time sepsis survivor Mary Millard, as she talks about her journey and how the T2Bacteria Panel test could have helped improve her outcome.
Contact us to request a demo of the T2Bacteria Panel!
1. Nguyen, M. H., et al. Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections. A Diagnostic Accuracy Study. Annals of Internal Medicine. 2019.
2. Voigt, Christopher, et al. “The T2Bacteria assay Is a sensitive and rapid detector of bacteremia that can be initiated in the emergency department and has potential to favorably influence subsequent therapy.” The Journal of emergency medicine 58.5 (2020): 785-796.
3. Karlowsky, JA, et al. Annals of Clinical Microbiology and Antimicrobials, 2004
* A combination of samples was run in both the prospective and contrived arms of the study. T2Bacteria showed an overall average sensitivity of 90% in the prospective arm of the study, with an overall average PPA of 97% in the contrived arm of the study.